natgillin/translations-raw huggingface dataset:
Patienter med follikulært lymfom, som ikke responderede eller som fik sygdomsprogression under eller op til 6 måneder efter behandling med rituximab eller en behandling indeholdende rituximab *Stratificeringsfaktorer for analysen var refraktær type (rituximab monoterapi versus rituximab + kemoterapi) og antal tidligere behandlinger (≤ 2 versus >2).
IRC: Independent Review Committee; PFS: progression-free survival; HR: Hazard Ratio; CI: Confidence Intervals, NR = Not Reached # Patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen *Stratification factors for analysis were refractory type (rituximab monotherapy vs. rituximab + chemotherapy) and prior therapies (≤ 2 vs > 2).
Primært endepunkt Progressionsfri overlevelse vurderet af investigator Antal (%) patienter med hændelse Hazard ratio (95% konfidensinterval) p- værdi (stratificeret log-rank test*) 3-årig estimat af progressionsfri overlevelse (95% konfidensinterval) Vigtige endepunkter Progressionsfri overlevelse vurderet af en uafhængig komité Antal (%) patienter med hændelse Hazard ratio (95% konfidensinterval) p-værdi (stratificeret log-rank test*) Tid indtil næste anti-lymfom behandling Antal (%) patienter med hændelse Hazard ratio (95% konfidensinterval) p- værdi (stratificeret log-rank test*) Samlet overlevelse# Antal (%) patienter med hændelse Hazard ratio (95% konfidensinterval) p- værdi (stratificeret log-rank test*) Samlet responsrate** ved endt induktionsbehandling‡ (investigatorvurderet, CT) Respondere
IRC-assessed PFS (PFS-IRC) Number (%) of patients with event HR [95% CI] p-value (Log-Rank test, stratified*) Time to next anti-lymphoma therapy# Number (%) of patients with event HR [95% CI] p-value (Log-Rank test, stratified*) Overall Survival
Progressionsfri overlevelse, vurderet af en uafhængig komité, i patient-sub-grupper hos patienter med follikulært lymfom*# (GAO4753g /GADOLIN-studiet)
Figure 8 IRC-assessed PFS by patient subgroup in FL *# (Study GAO4753g/GADOLIN)
Blod og lymfesystem Meget almindelig
Musculoskeletal and connective tissue disorders Very common
Hazard ratio (95%
HR (95% CI)
Dosering
Premedication
Hvis patienten har oplevet en infusionsrelateret reaktion i den foregående infusion, start med administration på 50 mg/time.
If the patient experienced an IRR during the previous infusion administer at 50 mg/hr.
• patienter med tidligere ubehandlet indolent non-Hodkin lymfom, der fik Gazyvaro plus kemoterapi (bendamustin, CHOP, CVP) efterfulgt af Gazyvaro vedligeholdelsesbehandling hos patienter, der opnåede et respons, sammenlignet med rituximab plus kemoterapi efterfulgt af rituximab vedligeholdelsesbehandling hos patienter, der opnåede et respons (studie BO21223/GALLIUM)
GAO4753g/GADOLIN) that occurred at a higher incidence (difference of ≥ 2%) compared to the relevant comparator arm in at least one pivotal study in: · Patients with CLL receiving Gazyvaro plus chlorambucil compared with chlorambucil alone or rituximab plus chlorambucil (study BO21004/CLL11) · Patients with previously untreated iNHL receiving Gazyvaro plus chemotherapy (bendamustine, CHOP, CVP) followed by Gazyvaro maintenance in patients achieving a response, compared to rituximab plus chemotherapy followed by rituximab maintenance in patients achieving a response (study BO21223/GALLIUM) · Patients with iNHL who had no response to or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen receiving Gazyvaro plus bendamustine, followed by Gazyvaro maintenance in some patients, compared to bendamustine alone (study GAO4753g/GADOLIN) The incidences presented in Table 6 (all grades and Grades 3-5) are the highest incidence of that ADR reported from any of the three studies.
Hvis reaktionen har været meget kraftig, kan lægen vælge helt at stoppe behandlingen med Gazyvaro.
Your doctor may decide to stop treatment with Gazyvaro if you have a severe infusion related reaction.
• GAO4753g/GADOLIN (N=392): Patienter med indolent non-Hodgkin lymfom (81% af patienterne havde follikulært lymfom), som ikke havde responderet på eller som havde progredieret under eller op til 6 måneder efter behandling med rituximab eller et rituximabindeholdende behandlingsregime.
In a phase III, open label, multicentre, randomised clinical study (GAO4753g/GADOLIN), 396 patients with iNHL who had no response during treatment or who progressed within 6 months following the last dose of rituximab or a rituximab-containing regimen (including rituximab monotherapy as part of induction or maintenance treatment) were evaluated.
Patienter med kronisk lymfatisk leukæmi, med en co-morbiditetsscore >6 på CIRSskalaen (Cumulative Illness Rating Scale) samt CrCl <70 ml/min har højere risiko for infektioner, inklusive svære infektioner (se pkt.
Patients (CLL) with both CIRS > 6 and CrCl < 70 mL/min are more at risk of infections, including severe infections (see section 4.8).
Nedsat nyrefunition
Posology
2Bendamustin gives intravenøst på 1. og 2. behandlingsdag i alle behandlingsserier (serie 1-6) i en dosis på 90
2 Bendamustine is given intravenously on Days 1 and 2 of all treatment cycles (Cycles 1-6) at 90 mg/m2/day; CHOP and CVP according to standard regimens
Intravenøst kortikosteroid4 Afsluttet mindst 1 time inden infusion af
Oral analgesic/anti-pyretic2 At least 30 minutes before Gazyvaro infusion
Hazard ratio (95% konfidensinterval)
Hazard ratio (95% CI) p-value (Log-Rank test, stratifiedb) Overall survival
Når symptomerne er forsvundet, kan infusionen genoptages ved maksimalt halvdelen af den tidligere infusionshastighed (af den infusionshastighed, der anvendtes på det tidspunkt den infusionsrelaterede reaktion opstod).
Upon resolution of symptoms, the infusion can be restarted at no more than half the previous rate (the rate being used at the time that the IRR occurred) and, if the patient does not experience any IRR symptoms, the infusion rate escalation can resume at the increments and intervals as appropriate for the treatment dose (see Tables 4 and 5).
4.2, blev der observeret en lavere incidens af infusionsrelaterede reaktioner af alle grader.
In patients who received the recommended measures for prevention of IRRs as described in section 4.2, a decreased incidence of IRRs of all Grades was observed.
Infusionshastigheden kan øges i intervaller på op til 50 mg/time hver 30. minut til maksimalt 400 mg/ time.
The rate of infusion can be escalated in increments up to 50 mg/hr every 30 minutes to a maximum rate of 400 mg/hr.
Laboratorieafgivelser
Laboratory abnormalities
Infusionshastigheden kan øges i trin af 50 mg/time hver 30. minut til maksimalt 400 mg/time.
The rate of infusion can be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.
En opdateret RMP skal fremsendes:
Date of latest renewal:
cyster og polypper) Almindelig
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Common
I et, ublindet, randomiseret klinisk fase III-multicenterstudie (GAO4753g /GADOLIN), blev 396 patienter med indolent non-Hodgkin lymfom undersøgt.
The studies BO21223/GALLIUM and GAO4753g/GADOLIN enrolled patients with iNHL including FL.
I samtlige tilfælde tilpasses doserne, således at der opnås hæmoglobinniveauer, der forbliver inden for det anbefalede område.
In all cases the doses are adjusted to obtain haemoglobin levels that remain within the recommended range.
Nespo findes i forskellige styrker fra 10 til 500 mikrogram/ml.
Nespo exists in various strengths, from 10 to 500 micrograms per millilitre.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Nespo.
The Committee recommended that Nespo be given marketing authorisation.
Lavere doser kan være påkrævet til børn med nyresvigt i aldersgruppen op til 10 år.
Lower doses may be necessary for children with kidney failure aged 10 years or below.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Nespo til Dompé Biotec S.p.A.
The European Commission granted a marketing authorisation valid throughout the European Union for Nespo to Dompé Biotec S.p.A. on 8 June 2001.
Behandlingen med Nespo bør igangsættes af en læge med erfaring i behandling af de to ovennævnte former for anæmi.
Nespo treatment should be initiated by a doctor who has experience in treating either of the two types of anaemia mentioned above.
Dette sammendrag blev sidst ajourført i 09-2007.
This summary was last updated in 09-2007.©EMEA 2007
Darbepoetin alfa fremstilles ved rekombinant DNA-teknik: Det produceres af en celle, der har fået indsat et gen (DNA), som gør cellen i stand til at producere darbepoetin alfa.
Darbepoetin alfa is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes the cell able to produce darbepoetin alfa.
Dosering og dosisintervaller (hvor ofte Nespo anvendes) bliver tilpasset efter, hvordan behandlingen virker.
Doses and dose frequency (how often Nespo is given) are adjusted depending on the response.
Nespo virker ved at stimulere produktionen af røde blodlegemer på samme måde som naturligt erythropoietin.
Nespo works by stimulating the production of red blood cells in the same way as natural erythropoietin.
Nespo anvendes til behandling af anæmi (færre røde blodlegemer i blodet end normalt) hos to grupper
Nespo is used to treat anaemia (fewer red blood cells in the blood than normal) in two groups of patients:
Den anvendte dosis afhænger af, hvad Nespo anvendes til, og varierer fra 0,45 mikrogram/kg ugentligt (eller 0,75 mikrogram/kg hver anden uge) hos voksne og børn med nyresvigt, i aldersgruppen 11 år eller ældre, til 6,75 mikrogram/kg hver tredje uge hos kræftpatienter.
The dose used depends on why Nespo is used, varying from 0.45 micrograms per kilogram every week (or 0.75 micrograms/kg every other week) in adults and children with kidney failure aged 11 years or older, to 6.75 micrograms/kg every three weeks in cancer patients.
• voksne patienter, som har visse former for kræft og er i behandling med kemoterapi (kræftbekæmpende medicin), når kemoterapien bevirker, at knoglemarven ikke producerer tilstrækkeligt med blodceller.
• adult patients with certain types of cancer who are receiving chemotherapy (the medicines used to treat cancer), when the chemotherapy stops the bone marrow producing enough blood cells.
• voksne og børn i aldersgruppen 1 år eller ældre, der lider af anæmi, som skyldes kronisk nyresvigt, hvor kroppen producerer for lidt af det naturlige hormon erythropoietin
• adults and children over one year of age with anaemia caused by long-term kidney failure, when the body does not produce enough of the natural hormone erythropoietin,
Det vigtigste mål for virkningen hos patienter med nyresygdom var stigningen i hæmoglobin.
The main measure of effectiveness in patients with kidney disease was the increase in haemoglobin.
Udvalget for humanmedicinske lægemidler (CHMP) besluttede, at fordelene ved Nespo var større end risiciene til behandling af anæmi i forbindelse med kronisk nyresvigt hos voksne og pædiatriske patienter og symptomatisk anæmi hos voksne kræftpatienter med ikke-myeloid malignitet i kemoterapi.
The Committee for Medicinal Products for Human Use (CHMP) decided that Nespo's benefits are greater than its risks for the treatment of anaemia associated with chronic renal failure in adults and paediatric patients, and of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
Hvordan blev Nespo undersøgt?
How has Nespo been studied?
Nespo er også blevet undersøgt hos 124 børn med langvarig nyresygdom for at kontrollere, om det
Nespo has also been studied in 124 children with long-term kidney disease to check that it is absorbed in the same way as in adults.
Nespo må ikke anvendes af patienter, der kan være overfølsomme (allergiske) over for darbepoetin alfa eller andre af indholdsstofferne, eller af patienter med ikke-velkontrolleret forhøjet blodtryk.
Nespo should not be used in people who may be hypersensitive (allergic) to darbepoetin alfa or any of the other ingredients, or in patients who have poorly controlled high blood pressure.
Hæmoglobin er det protein i de røde blodceller, der transporterer ilt rundt i
Haemoglobin is the protein in red blood cells that carries oxygen around the body.
Virkningen af Nespo er undersøgt hos patienter med langvarig nyresygdom (hvor Nespo blev sammenlignet med rekombinant humant erythropoietin i fire undersøgelser med flere end 1 200 patienter) og hos patienter i kemoterapi for kræftformer som lungekræft, myelom eller lymfom, hvor Nespo blev sammenlignet med placebo (virkningsløs behandling) i to undersøgelser med 669 patienter.
The effectiveness of Nespo has been studied in patients with long-term kidney disease, where it was compared with recombinant human erythropoietin in four studies involving over 1,200 patients, and in patients receiving chemotherapy for cancer such as lung cancer, myeloma or lymphoma, where it was compared with placebo (a dummy treatment) in two studies involving 669 patients.
Mangel på naturligt erythropoietin er ligeledes medvirkende til anæmien hos patienter i kemoterapi.
A lack of natural erythropoietin is also one of the causes of anaemia in patients receiving chemotherapy.
Nespo leveres klar til brug i fyldte sprøjter eller i fyldte injektionspenne, som kan anvendes af patienten selv eller plejepersonalet.
Nespo is supplied ready for use in a pre-filled syringe or pre-filled pen, which can be used by the patient or their carer.
De hyppigste bivirkninger af Nespo (som kunne observeres hos mellem 1 og 10 patienter ud af 100) er hovedpine, for højt blodtryk, trombose (blodpropper), smerte på injektionsstedet, ledsmerter og væskeansamling i lemmerne.
The most common side effects with Nespo (seen in between 1 and 10 patients in 100) are headache, hypertension (high blood pressure), thrombosis (blood clots), injection site pain, arthralgia (joint pain) and peripheral oedema (fluid retention).
den 8. juni 2001.
The marketing authorisation was renewed on 8 June 2006.
EUROPÆISK OFFENTLIG VURDERINGSRAPPORT (EPAR) NESPO
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NESPO EPAR summary for the public
De kræftformer, hvor Nespo kan anvendes, er ikke-myeloide
The types of cancer where Nespo can be used are ‘non-myeloid' (do not affect the bone marrow).
Hvordan virker Nespo?
How does Nespo work?
Nespo var lige så effektivt som rekombinant human erythropoietin til at øge hæmoglobinniveauet hos patienter med nyresygdom og til at fastholde dette niveau, efter at det var bedret.
Nespo was as effective as human recombinant erythropoietin at increasing the haemoglobin levels in patients with kidney disease, and at keeping these levels maintained after they had been improved, whether given as an intravenous or subcutaneous injection.
Hos kræftpatienter i kemoterapi var blodtransfusion nødvendig hos færre patienter i Nespo-gruppen end i placebogruppen.
In cancer patients receiving chemotherapy, fewer patients treated with Nespo needed a blood transfusion compared with those given placebo.
Den fuldstændige liste over de indberettede bivirkninger ved Nespo
For the full list of all side effects reported with Nespo, see the Package Leaflet.
Hormonet erythropoietin stimulerer knoglemarven til at producere flere røde blodlegemer.
A hormone called erythropoietin stimulates the production of red blood cells from the bone marrow.
Darbepoetin alfa, det aktive stof i Nespo, virker fuldstændig som det naturlige erythropoietin, der produceres af kroppen, men har ikke helt samme opbygning.
Darbepoetin alfa, the active substance in Nespo, acts exactly like the natural erythropoietin made by the body, but it is very slight different in its structure, and this means that darbepoetin alfa has a longer duration of action, and can be given less often than natural erythropoietin.
Nespo er en injektionsvæske, der leveres i hætteglas, fyldte sprøjter og fyldte injektionspenne.
Nespo is a solution for injection in a vial, a pre-filled syringe or a pre-filled pen.
Hvilken fordel viser undersøgelserne, at der er ved Nespo?
What is the risk associated with Nespo?
Mangel på naturligt erythropoietin er hovedårsagen til anæmien hos patienter med langvarigt nyresvigt.
In patients with long-term kidney failure, the main cause of their anaemia is a lack of natural erythropoietin.
Hos patienter i kemoterapi var det vigtigste mål for virkningen, hvor mange færre
In patients receiving chemotherapy, the main measure of effectiveness was the reduction in number of patients who needed a blood transfusion.
Yderligere oplysninger fremgår af indlægssedlen.
The medicine can only be obtained with a prescription.
Yderligere oplysninger vedrørende brug fremgår af indlægssedlen.
See the Package Leaflet for full instructions for use.
Grækenland Chiesi Hellas A.E.B.E.
Chiesi Hellas A.E.B.E.
9 µg dosis
9µg Dose
Nederlandene Chiesi Pharmaceuticals B.V.
Netherlands Chiesi Pharmaceuticals B.V.
Grækenland Zwitter Pharmaceuticals επε
Zwitter Pharmaceuticals επε
4,5 µg dosis
4.5µg Dose
Inhalationspulver, hård kapsel
Inhalation Powder, Hard Capsule
Grækenland Png Gerolymatos Medical A.E.
Png Gerolymatos Medical A.E.
Grækenland Iasis Pharma
Iasis Pharma
Novartis Pharmaceuticals Uk Limited
Novartis Pharmaceuticals Uk Limited Miflonide
Rumænien Medochemie Romania S.R.L.
Medochemie Romania S.R.L.
Inhalationsspray, suspension
Pressurised Inhalation, Suspension
Nederlandene Astrazeneca Bv
Netherlands Astrazeneca Bv
Formoterolfumaratdihydrat 1,08 mg, beclometasondipropionat 18 mg
Formoterol Fumarate Dihydrate 1,08 Mg, Beclometasone Dipropionate 18 Mg
Flunisolid 25 mg flaske, salbutamol 10 mg flaske
Flunisolide 25mg Bottle, Salbutamol 10mg Bottle
Slovenien Glaxosmithkline D.O.O., Ljubljana Flixotide
Glaxosmithkline D.O.O., Ljubljana Flixotide
Clenil Compositum Beclometasondipropionat 0,8 mg/2 mi, salbutamolsulfat 1 928 mg/2 mi
Clenil Compositum Beclometasone Dipropionate 0.8mg/2 Ml, Salbutamol Sulfate 1.928mg/2 Ml
Slovenien Glaxosmithkline D.O.O., Ljubljana Seretide Diskus
Glaxosmithkline D.O.O., Ljubljana Seretide Diskus
Inhalationsspray
Pressurised Inhalation
Grækenland Medicair Bioscience Laboratories S.A
Medicair Bioscience Laboratories S.A Bocacort-S
Budezonid Lek-Am Budesonid 400 µg inhalation
Budezonid Lek-Am Budesonide 400µg Inhalation
Clenil Compositum Beclometasondipropionat 50 µg aktivering, salbutamolsulfat 120 µg aktivering
Clenil Compositum Beclometasone Dipropionate 50µg Actuation, Salbutamol Sulfate 120µg Actuation
Bulgarien Sopharma Ad
Sopharma Ad
Slovenien Lek Pharmaceuticals D.D.
Lek Pharmaceuticals D.D.
Budesonid 0,8 mg kapsel
Budesonide 0.8mg Capsule
Nederlandene Glaxosmithkline B.V.
Netherlands Glaxosmithkline B.V.
Budesonid 400 µg inhalation
Budesonide 400µg Inhalation
Budezonid Lek-Am Budesonid 200 µg inhalation
Budezonid Lek-Am Budesonide 200µg Inhalation
Budesonid 1 mg ampul
Budesonide 1mg Ampoule
Salbutamolsulfat 0,602 mg hætteglas, flunisolid 0,5 mg hætteglas
Salbutamol Sulfate 0.602mg Vial, Flunisolide 0.5mg Vial
Samtoral Diskus Standard Fluticasonpropionat 250 µg dosis, salmeterol 50 µg dosis
Samtoral Diskus Standard Fluticasone Propionate 250µg Dose, Salmeterol 50µg Dose
Fluticasonpropionat 2 mg/2 ml
Fluticasone Propionate 2mg/2ml
Fluticasone Propionate 125µg Capsule Inhalationspulver, hård kapsel
Fluticasone Propionate 125µg Capsule Inhalation Powder, Hard Capsule
Næsespray, suspension
Nasal Spray, Suspension
Beclometason Ratiopharm Beclometasondipropionat 0,25 mg/18,7 g
Beclometason Ratiopharm Beclometasone Dipropionate 0.25mg/18.7g
Budosenid 320 mcg, formoterolfumaratdihydrat 9 mcg
Budosenide 320mcg, Formoterol Fumarate Dihydrate 9mcg
Fluticasonpropionat 500 mikrogram, salmeterolxinafoat 50 mikrogram
Fluticasone Propionate 500 Microgram, Salmeterol Xinafoate 50 Microgram
Grækenland Win Medica Ltd
Win Medica Ltd
Beclometasondipropionat 250 µg/59,2 mg
Beclometasone Dipropionate 250µg/59.2 Mg
Budesonid, mikroniseret 200 µg dosis Inhalationspulver
Budesonide, Micronised 200µg Dose Inhalation Powder
Grækenland Glaxosmithkline Aebe
Glaxosmithkline Aebe
Fluticasonpropionat 0,05 mg/2 ml
Fluticasone Propionate 0.05mg/2ml
Fluticasonpropionat 0,5 mg, salmeterolxinafoat 0,073 mg
Fluticasone Propionate 0,5 Mg, Salmeterol Xinafoate 0,073 Mg
Budesonid 0,2 mg/0,05 ml
Budesonide 0.2mg/0.05ml
Budesonid 100 µg enheder
Budesonide 100µg Units
Ucb Pharma Gmbh (Monheim De) Atmadisc Forte Diskus
Ucb Pharma Gmbh (Monheim De)
Fluticasonpropionat 250 µg dosis, salmeterol 50 µg dosis, lactosemonohydrat 24,677 mg dosis
Fluticasone Propionate 250µg Dose, Salmeterol 50µg Dose, Lactose Monohydrate 24.677mg Dose
Budesonid 800 µg enheder
Budesonide 800µg Units
Beclometason dipropionat 100 µg/50 µl
Beclometasone Dipropionate 100µg/50 µl
Beclometasondipropionat 100 g/10ml
Beclometasone Dipropionate 100g/10ml
Fluticasonpropionat 0,25 mg, salmeterolxinafoat 0,073 mg
Fluticasone Propionate 0,25 Mg, Salmeterol Xinafoate 0,073 Mg
Budesonid, micronised 0,4 mg aktivering
Budesonide, Micronised 0.4mg Actuation
Grækenland Astrazeneca S.A.
Astrazeneca S.A.
Beclometason dipropionat 50 µg/50 µl
Beclometasone Dipropionate 50µg/50 µl
Cyclocaps Beclometason Beclometasondipropionat 200 µg enheder
Cyclocaps Beclometason Beclometasone Dipropionate 200µg Units
Grækenland Orion Corporation
Belgium Orion Corporation
Budosenid 160 mcg, formoterolfumaratdihydrat 4,5 mcg
Budosenide 160mcg, Formoterol Fumarate Dihydrate 4.5mcg
Budesonid 320 µg dosis, formoterolfumaratdihydrat Ph.Eur.
Budesonide 320µg Dose, Formoterol Fumarate Dihydrate Ph.Eur.
Cyclocaps Beclometason Beclometasondipropionat 100 µg enheder
Cyclocaps Beclometason Beclometasone Dipropionate 100µg Units
Bulgarien Glaxosmithkline Eood
Glaxosmithkline Eood
Beclometasondipropionat 100 µg inhalation, formoterolfumarat 6 µg inhalation
Beclometasone Dipropionate 100µg Inhalation, Formoterol Fumarate 6µg Inhalation
Beclometasondipropionat 50 µg/59 mg
Beclometasone Dipropionate 50µg/59 Mg
Cyclocaps Beclometason Beclometasondipropionat 400 µg enheder
Cyclocaps Beclometason Beclometasone Dipropionate 400µg Units
Budesonid, Micronised 0,2 mg aktivering
Budesonide, Micronised 0.2mg Actuation
Fluticasonpropionat 250 mcg/dosis Inhalationspulver
Fluticasone Propionate 250mcg/Dose Inhalation Powder
Beclometasondipropionat 250 g/78 mg
Beclometasone Dipropionate 250g/78mg
Budesonid 160 µg dosis, formoterolfumaratdihydrat Ph.Eur.
Budesonide 160µg Dose, Formoterol Fumarate Dihydrate Ph.Eur.
Budesonid, mikroniseret 400 µg dosis Inhalationspulver
Budesonide, Micronised 400µg Dose Inhalation Powder
Fluticasonpropionat 500 µg inhalation, salmeterol 50 µg inhalation
Fluticasone Propionate 500µg Inhalation, Salmeterol 50µg Inhalation
Budesonid 0,25 mg ampul
Budesonide 0.25mg Ampoule
Nederlandene Elpen Pharmaceutical Co. Inc.
Netherlands Elpen Pharmaceutical Co. Inc.
Fluticasonpropionat 100 µg
Fluticasone Propionate 100µg
Budesonid 320 µg inhalation, formoterolfumaratdihydrat 9 µg inhalation
Budesonide 320µg Inhalation, Formoterol Fumarate Dihydrate 9µg Inhalation
Fluticasonpropionat 220 µg sug
Fluticasone Propionate 220µg Puff
Symbicort Mite Turbuhaler Budesonid 160 µg dosis, formoterolfumaratdihydrat 4,5 µg dosis
Symbicort Mite Turbuhaler Budesonide 160µg Dose, Formoterol Fumarate Dihydrate 4.5µg Dose
Fluticasonpropionat 500 µg dosis, salmeterol 50 µg dosis, lactosemonohydrat 24,677 mg dosis
Fluticasone Propionate 500µg Dose, Salmeterol 50µg Dose, Lactose Monohydrate 24.677mg Dose
Budesonid 0,2 mg dosis
Budesonide 0.2mg Dose
Symbicort Forte Turbohaler Budesonid 320 µg dosis, formoterolfumaratdihydrat 9 µg dosis
Symbicort Forte Turbohaler Budesonide 320µg Dose, Formoterol Fumarate Dihydrate 9µg Dose
Salmeterol 25 µg/dosis, fluticasonpropionat 125 µg/dosis
Salmeterol 25µg/Dose; Fluticasone Propionate 125µg/Dose
Beclometasondipropionat 0,2 mg
Beclometasone Dipropionate 0.2mg Dose
Budesonid 160 µg inhalation, formoterolfumaratdihydrat 4,5 µg inhalation
Budesonide 160µg Inhalation, Formoterol Fumarate Dihydrate 4.5µg Inhalation
Fluticasonpropionat 125 µg
Fluticasone Propionate 125µg
Symbicort Forte Turbuhaler Budesonid 320 µg dosis, formoterolfumaratdihydrat 9 µg dosis
Symbicort Forte Turbuhaler Budesonide 320µg Dose, Formoterol Fumarate Dihydrate 9µg Dose